Recent Research Analysts’ Ratings Updates for Sarepta Therapeutics (SRPT)

A number of firms have modified their ratings and price targets on shares of Sarepta Therapeutics (NASDAQ: SRPT) recently:

• 11/27/2024 – Sarepta Therapeutics had its price target lowered by analysts at Piper Sandler from $200.00 to $182.00. They now have an “overweight” rating on the stock.
• 11/27/2024 – Sarepta Therapeutics had its price target lowered by analysts at Needham & Company LLC from $205.00 to $202.00. They now have a “buy” rating on the stock.
• 11/25/2024 – Sarepta Therapeutics is now covered by analysts at HC Wainwright. They set a “sell” rating and a $80.00 price target on the stock.
• 11/20/2024 – Sarepta Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/12/2024 – Sarepta Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/7/2024 – Sarepta Therapeutics was upgraded by analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating. They now have a $167.00 price target on the stock, up previously from $152.00.
• 11/7/2024 – Sarepta Therapeutics had its price target lowered by analysts at Robert W. Baird from $200.00 to $193.00. They now have an “outperform” rating on the stock.
• 11/7/2024 – Sarepta Therapeutics had its price target lowered by analysts at Evercore ISI from $179.00 to $170.00. They now have an “outperform” rating on the stock.
• 11/7/2024 – Sarepta Therapeutics had its price target raised by analysts at Guggenheim from $148.00 to $150.00. They now have a “buy” rating on the stock.
• 11/7/2024 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
• 10/21/2024 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $182.00 price target on the stock.
• 10/21/2024 – Sarepta Therapeutics is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $165.00 price target on the stock.
• 10/14/2024 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $205.00 price target on the stock.
• 10/10/2024 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $150.00 price target on the stock.
• 10/4/2024 – Sarepta Therapeutics had its price target raised by analysts at Royal Bank of Canada from $181.00 to $182.00. They now have an “outperform” rating on the stock.

Sarepta Therapeutics Trading Up 5.7 %

Shares of SRPT opened at $137.94 on Friday. The business’s 50-day moving average price is $122.16 and its 200 day moving average price is $131.43. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $13.18 billion, a P/E ratio of 110.35 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1-year low of $78.67 and a 1-year high of $173.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics in the second quarter worth $31,000. Sunbelt Securities Inc. grew its stake in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank increased its position in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth about $43,000. Finally, Riggs Asset Managment Co. Inc. lifted its holdings in shares of Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.